Differential Interactions of Id Proteins with Basic-Helix-Loop-Helix Transcription Factors*

(Received for publication, March 21, 1997, and in revised form, June 5, 1997)

Kenneth Langlands Dagger , Xiaoying Yin Dagger , Geetha Anand Dagger and Edward V. Prochownik Dagger §par

From the Dagger  Section of Hematology/Oncology, Children's Hospital of Pittsburgh, The § Department of Molecular Genetics and Biochemistry, and  The University of Pittsburgh Cancer Institute, The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Dimerization of three Id proteins (Id1, Id2, and Id3) with the four class A E proteins (E12, E47, E2-2, and HEB) and two groups of class B proteins, the myogenic regulatory factors (MRFs: MyoD, myogenin, Myf-5 and MRF4/Myf-6), and the hematopoietic factors (Scl/Tal-1, Tal-2, and Lyl-1) were tested in a quantitative yeast 2-hybrid assay. All three Ids bound with high affinity to E proteins, but a much broader range of interactions was observed between Ids and the class B factors. Id1 and Id2 interacted strongly with MyoD and Myf-5 and weakly with myogenin and MRF4/Myf-6, whereas Id3 interacted weakly with all four MRFs. Similar specificities were observed in co-immunoprecipitation and mammalian 2-hybrid analyses. No interactions were found between the Ids and any of the hematopoietic factors. Each Id was able to disrupt the ability of E protein-MyoD complexes to transactivate from a muscle creatine kinase reporter construct in vivo. Finally, mutagenesis experiments showed that the differences between Id1 and Id3 binding map to three amino acids in the first helix and to a small cluster of upstream residues. The Id proteins thus display a signature range of interactions with all of their potential dimerization partners and may play a role in myogenesis which is distinct from that in hematopoiesis.


INTRODUCTION

An increasingly important role is ascribed to protein-protein interactions in the regulation of cellular growth and differentiation pathways. Dimerization serves to convert inactive monomeric molecules into transcriptionally active dimeric complexes at specific times during cellular development. Deletional analysis has identified a number of evolutionarily conserved regions that mediate these interactions. One such region, commonly associated with transcription factors involved in a range of proliferative and differentiation pathways, is the basic-helix-loop-helix (bHLH)1 (1). This domain is conserved from yeast to mammals and is composed of a positively charged basic region followed by two amphipathic alpha -helices separated by a spacer loop. Dimers are stabilized by a series of hydrophobic and electrostatic interactions between the helices of compatible molecules (2-5). The juxtaposition of two basic regions resulting from dimerization forms a DNA binding interface able to insert into the major groove in a sequence-specific manner (2, 6). Although bHLH proteins have no discernible DNA binding activity as monomers, dimers recognize a consensus DNA sequence (CANNTG), termed the E box (4, 7-9).

bHLH transcription factors can be broadly placed into two categories (reviewed in Ref. 10). The class A factors, or E proteins, (E2-2, HEB, and the E2A gene products E12 and E47) are expressed in a virtually ubiquitous pattern and are able to dimerize efficiently with tissue-restricted class B factors to activate gene expression (1, 11-13). Because each factor contributes a specific DNA recognition half-site, class A and class B heterodimeric complexes and class A hetero- or homodimers theoretically provide distinct combinatorial E box binding specificities (7). Class B members thus far characterized include the myogenic regulatory factors (MRFs) involved in skeletal muscle development (MyoD, myogenin, Myf-5, and MRF4/Myf-6) and the hematopoietic factors (Scl/Tal-1, Tal-2, and Lyl-1) (14-21). Mammalian homologues of the Drosophila bHLH achaete scute genes (mash1 and -2) have been implicated in neuronal development as has neurod (beta2) which also has a role in insulin regulation (22-24). A range of other class B bHLH proteins have been associated with early mesoderm formation and later muscle development (Twist), adipocyte development (Add1), and skeleton formation (Scl-1) (25-27). E box motifs have been identified in the enhancer elements of a number of bHLH factor-regulated genes such as myosin heavy chain, immunoglobulins, and chymotrypsin (10).

The formation of active class A-class B complexes is modulated by the Id (inhibitor of DNA binding) family members. The four Id proteins identified thus far have an HLH domain that lacks the amino-terminal associated basic region necessary for DNA binding (28-33). Id proteins act to sequester class A factors, inhibiting the formation of active class A-class B heterodimers and are therefore considered to act as dominant negative regulators of differentiation pathways (28, 34, 35). Ids are expressed in a largely overlapping but distinct fashion during development, with the highest levels generally being achieved during embryogenesis (33). Significant Id levels persist in a range of actively proliferating tissues and in some tumor cell lines (28, 33). Rapid Id down-regulation has been reported in myoblasts and hematopoietic cells during terminal differentiation, consistent with their negative regulatory role (28, 34). Indeed, forced Id expression has been shown to inhibit the differentiation of each of these cell types (36-40). Because considerable overlap exists in the expression patterns of Id proteins, redundancy in their function has been inferred (30, 33).

Ids are known to bind avidly to class A factors such as E47, weakly to the myogenic factors, and poorly, if at all, to the hematopoietic factors (28, 34, 41). This has led to the assumption that transcriptional control is exerted primarily at the level of Id-class A interactions. However, these studies were performed with select members of the class A and class B families. Thus far, no exhaustive studies exist to compare the relative strengths of interactions among a broader range of family members.

The yeast 2-hybrid system has become an increasingly popular method for assessing protein-protein interactions and has been employed previously to study a subset of bHLH interactions (35, 42-44). We sought to develop a quantitative yeast 2-hybrid assay to investigate interactions of three Id proteins with a range of class A and class B factor targets. Our observations, confirmed and extended by co-immunoprecipitation (IP) of in vitro translated proteins and mammalian 2-hybrid analyses, indicate that discrete and reproducible differences exist in relative binding preferences among the Id proteins. As expected, Id proteins bound avidly to all the class A factors tested, although a range of affinities were apparent. A broader range of affinities for myogenic factors was observed, and no interactions with the hematopoietic factors were seen despite their expression in functional form. Transient transfection studies in C3H myoblasts employing a muscle-specific creatinine kinase- chloramphenicol acetyltransferase (CAT) reporter vector provided independent confirmation of the hierarchical interactions of Id proteins with class A factors. Site-directed mutagenesis enabled us to map the regions responsible for establishing Id dimerization preferences to the first helix of the HLH domain and to residues immediately adjacent to this. Our findings have implications for the mechanism by which Id proteins influence class A and class B interactions and for the roles played by different Id proteins in tissue-specific gene regulation.


EXPERIMENTAL PROCEDURES

Plasmid Construction

Parental yeast vectors pGBT9 and pGAD were kindly supplied by Dr. S. Elledge (Baylor College of Medicine). Parental expression vectors for mammalian 2-hybrid analysis, pSG424 and pNLVP16, were obtained from Drs. C. Dang (Johns Hopkins University School of Medicine) and M. Green (University of Massachusetts) (45, 46). Murine Id1 was obtained from Dr. H. Weintraub (Fred Hutchinson Cancer Research Center), and murine Id2 and Id3 cDNAs were obtained from Dr. D. Nathans (Johns Hopkins University) (28, 30, 34). Fragments encoding the HLH regions plus 15-20 flanking amino acid residues were generated by PCR primers incorporating EcoRI (forward primer) and BamHI (reverse primer) sites and cloned directionally and in-frame into pGAD, pGBT9, and pSG424. The fragments amplified encoded amino acids 73-138 of Id1, 72-140 of Id2, and 28-91 of Id3. All products were sequenced to confirm the fidelity of the PCR amplification reaction. Full-length cDNAs were cloned into pRcCMV (Invitrogen, San Diego, CA) for use in in vitro transcription/translation reactions and transient transfection assays. Murine MyoD, murine myogenin, and human Myf-5 were supplied by Dr. D. Shapiro (St. Jude Children's Research Hospital) and rat MRF4/Myf-6 by Dr. S. Konieczny (Purdue University) (8, 15, 16, 20). Fragments encoding the bHLH domains were again amplified by PCR, incorporating EcoRI and BamHI sites for MyoD or BamHI and PstI sites for myogenin, Myf-5, and MRF4/Myf-6 and cloned in-frame into pGBT9 and pGAD424. The regions amplified included codons 83-184 of MyoD, 55-155 of myogenin, 56-143 of Myf-5, and 65-168 of MRF4/Myf-6. Due to the presence of an internal PstI site in the second helix of Myf-5 and MRF4/Myf-6, these were cloned as BamHI/blunt fragments. The bHLH domains from MyoD and Myf-5 were also subcloned in-frame into pNLVP16 as blunt-ended fragments. Full-length MyoD and MRF4/Myf-6 cDNAs were cloned into pRcCMV. The cDNAs encoding each of the class A factors were isolated from a yeast 2-hybrid screen of a murine embryo library in the pGAD10 vector (CLONTECH, Palo Alto, CA) using an Id2 bait. These contained residues 118-264 of murine E47 (A1), residues 379-666 of murine E2-2 (ME-2), and residues 574-729 of murine HEB (Alf-1) (47-49). The E47 fragment was also cloned into both pNLVP16 and pGBT9. A carboxyl-terminal bHLH containing fragment of human E12 (residues 508-654) in the pAS1 vector, a gift from Dr. E. Olsen (University of Texas), was excised and sub-cloned into pGAD424 (44). None of the class A clones contained the putative leucine zipper regions that are associated with transcriptional activation domains (50). An almost full-length E12 clone in bluescript (E12R, a gift from Dr. H. Weintraub), including the putative leucine zipper domain, was used for in vitro translation (6). Full-length E12 and E47 in the mammalian expression vector pGK were a gift from Dr. G. Kato (Johns Hopkins University School of Medicine). The cDNAs for human hematopoietic factors Scl/Tal-1, Tal-2, and Lyl-1 were provided by Drs. I. Kirsch (National Cancer Institute), R. Baer (University of Texas), and M. Cleary (Stanford University), respectively (14, 19, 21). bHLH domains were again amplified by PCR with primers containing EcoRI and BamHI sites and were cloned in-frame into both pGAD424 and PGBT9. The amplified fragments encoded amino acids residues 66-138 of Scl/Tal-1, 2-69 of Tal-2, and 127-200 of Lyl-1. Full-length Scl/Tal-1 was subcloned into pBluescript SK+ (Stratagene, La Jolla, CA). The multimerized gal4:CAT reporter construct pGal5E472CAT was supplied by Dr. M. Green (51). The muscle creatinine kinase (MCK) CAT construct was obtained from Dr. S. Hauschka (University of Washington).

Yeast 2-Hybrid System

This was performed according to the protocol developed in the laboratory of Dr. S. Elledge, who also supplied the Saccharomyces cerevisiae strain Y153 (MATa, leu2-3, trp1-901, his3-Delta 200, ura5-32, ade2-101, gal4Delta , gal80Delta GGAL-HIS3, LYS2::GAL-HIS3). Potential partner genes in either pGAD424 or pGBT9 were co-transformed into yeast by a lithium chloride/polyethylene glycol precipitation method (52). Semi-quantitative determination of interaction strengths was performed by in situ assessment of beta -galactosidase activity.

Quantitative beta -Galactosidase Assay

Yeast transformants were grown to stationary phase in complete EGG medium containing 2% ethanol, 2% galactose, and 3% glycerol and lacking tryptophan and leucine. 107 cells were pelleted and resuspended in 50 µl of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM MgCl2, 50 mM beta -mercaptoethanol) containing 0.01% SDS. Two microliters of CHCl2 were added followed by two cycles of freeze-thawing in liquid nitrogen. Lysates were transferred to 96-well plates, and 50 µl of a fluorogenic substrate (8 mM 3-carboxyumbelliferyl-beta -D-galactopyranoside, Molecular Probes Inc., Eugene, OR) was added. After 30 min, 100 µl of stop buffer (300 mM glycine, 15 mM EDTA, pH 11.5) was added, and the reactions were allowed to stabilize for 1 h. Fluorescence was determined in a Perkin-Elmer microtiter plate reader (Foster City, CA; excitation 390 nm, emission 460 nm), and the amount of beta -galactosidase synthesized was calculated relative to a dilution series of beta -galactosidase enzyme standards (Sigma) assayed simultaneously with the yeast lysates. All assays were performed in triplicate with standard errors of less than 10% in each case. None of the individual vectors used in this series displayed a background higher than 10 pg of beta -galactosidase enzyme/107 cells which represents the lower limit of detection with this assay.

Western Blot Analysis

Yeast were grown in EGG medium until they reached stationary phase. They were then pelleted and subject to two cycles of freeze-thawing followed by boiling in standard SDS-polyacrylamide gel electrophoresis (PAGE) lysis buffer for 10 min to ensure complete lysis (53). 100 µg of protein was resolved by 12% PAGE and transferred to Immobilon-P membranes (Sigma) by semi-dry electroblotting. Membranes were preincubated in wash solution (1 × phosphate-buffered saline + 0.1% Tween 20). This was followed by a 1-h incubation in block solution (5% non-fat dry milk powder, phosphate-buffered saline + 0.1% Tween 20) containing either an anti-yeast gal4 DNA binding domain or activation domain antibody (at 1:500 and 1:2000 dilutions, respectively) (Upstate Biotechnology Inc., Lake Placid, NY). Membranes were washed four times before the addition of a horseradish peroxidase-linked goat anti-mouse antibody (1:1000 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in blocking solution and incubated for a further 1 h at room temperature. After a further four washes, proteins were visualized using an enhanced chemiluminescence detection kit according to the manufacturer's instructions (Amersham International, Buckinghamshire, UK).

In Vitro Transcription/Translation and Co-immunoprecipitation

Full-length E12, Id1, Id2, Id3, Scl/Tal-1, MyoD, and MRF4/Myf-6 cDNAs in either pBluescript SK+ or pRcCMV were transcribed and translated in vitro using a coupled reticulocyte lysate kit (TNT, Promega, Madison, WI) in the presence of [35S]methionine (1 mCi/mmol). Labeled proteins were mixed and incubated at 37 °C for 20 min before the addition of 100 µl of IP buffer (250 mM NaCl, 0.25% Nonidet P-40, 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol). Anti-Id, E12, or MyoD polyclonal antibodies were added and reactions incubated on ice for 30 min prior to the addition of 30 µl of a 1:1 mix of protein A-Sepharose (Bio-Rad) in IP buffer. After a further 60 min incubation, samples were washed four times in IP buffer before resolution by 12% SDS-PAGE. The intensity of each partner was quantified by PhosphorImage analysis (Molecular Dynamics) using Image-Quant software and normalized relative to methionine content of each protein. The value was then expressed as a ratio of the amount of input proteins. All antibodies were tested for cross-reactivity and shown to be specific for their respective protein under the conditions described here.

Mammalian 2-Hybrid Analysis/Transient Transfections

5 µg of each vector DNA was introduced into HeLa cells by calcium phosphate precipitation, and the cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% calf serum (Life Technologies, Inc.) (54). All transfections included a CMV beta -galactosidase reporter (CLONTECH) to standardize transformation efficiencies. CAT assays were performed on cell lysates harvested after 48 h and relative conversion calculated by PhosphorImage analysis.

A determination of the ability of Ids to repress E protein-MyoD interactions was performed in C3H myoblasts. The amounts of MyoD and E protein vector DNAs used were determined empirically so as to generate the maximum amount of transcriptional activation in combination over either factor alone, prior to determining the influence of co-transfected Id. This ensured that CAT activity was a reflection of a specific MyoD-E2A interaction, minimizing the influence of additional endogenous factors. 2 days post-transfection, DMEM + 10% calf serum was replaced with DMEM + 2% horse serum, and incubation was continued for a further 2 days. Under these conditions, endogenous Id levels are repressed, allowing for myogenic differentiation to proceed (55). All transfections were adjusted to give uniform DNA concentrations with the empty pRcCMV vector.

Id Protein Helix Swaps and Site-directed Mutagenesis

Helix swaps between Id1 and Id3 were generated by PCR amplification of individual helices followed by a "cut and paste" cloning strategy. Sixteen residues upstream of the amino terminus and 14 residues downstream of the carboxyl terminus of each HLH domain were maintained to promote correct folding. A fragment of Id1 encompassing helix 1 was amplified with a forward primer containing an EcoRI site. The reverse primer mapped to the helix 1/loop junction and contained a BamHI site. A SmaI site was introduced at the helix 1/loop boundary (residues 102 and 103 of Id1) where the codons CCC ACC were altered to CCC GGG. EcoRI/BamHI-digested fragments were cloned into pBluescript SK+ to create plasmid A. Helix 2 from Id3 was amplified from a 5' primer derived from the loop/helix 2 region, also containing a SmaI site and a 3' primer containing a BamHI site. BamHI/SmaI-digested fragments were then ligated into BamHI/SmaI-digested plasmid A, thus generating an Id1/3 chimera (plasmid B). A complementary approach was taken to constructing the Id3/1 chimera. Finally, EcoRI/BamHI fragments were excised from plasmid B and cloned into the yeast vector pGBT9 or into an m13 vector for further point mutagenesis. Oligonucleotide-mediated site-directed mutagenesis was performed with the Muta-gene kit (Bio-Rad) according to the manufacturer's recommendations using the chimeric Id1/3 or Id3/1 single-stranded phage DNAs. All clones were completely sequenced to ensure the presence of the desired mutation prior to subcloning into pGBT9. Each construct was tested for interaction with pGAD E12 and shown to interact with consistent affinity.


RESULTS

Yeast 2-Hybrid Analysis

A quantitative 2-hybrid approach was used to study interactions between Id proteins and a series of class A and class B targets expressed as gal4 binding domain and gal4 transactivation domain fusions, respectively (Fig. 1). All Id-class A interactions were determined to be quite strong by this assay (Fig. 1A). Interactions varied over a 5-fold range from the weakest (Id2-HEB) to the strongest (Id2-E47). The consistently strong Id-class A interactions observed stand in contrast to those seen between the Ids and the class B myogenic factors (Fig. 1B). These latter interactions were considerably weaker than those of Id-class A interactions and showed a far greater degree of variability. Id2 displayed the strongest binding which, in the case of MyoD and Myf-5, was 3-4-fold more avid than that of the corresponding Id1 interactions. In turn, Id1 bound MyoD and Myf-5 with a 5-10-fold greater affinity than Id3 which demonstrated barely detectable interaction with any of the myogenic factors. Of note, however, was that the strength of the Id2-Myf-5 and Id2-MyoD interactions rivaled the weakest Id-class A factor interactions. MyoD and Myf-5 showed the strongest interactions with all three Ids tested. Although Id3 bound weakly, if at all, to the myogenic factors, its binding to class A factors was comparable to that of the other Ids (Fig. 1A). Hence the differences in binding seen here cannot be attributed to differential expression. This was also confirmed by Western blot analysis of yeast lysates showing comparable levels of expression of all proteins under study (Fig. 2). When tested for their ability to bind the class A factors E47 or E12, all the myogenic factors (including MRF4/Myf-6) interacted strongly (Fig. 1B), again indicating that the differences in myogenic factor-Id binding were not due to relative differences in MRF protein expression. None of the hematopoietic factors displayed discernible interactions with the Id proteins, whereas all were found to interact with the class A target E2-2 (Fig. 1C).


Fig. 1. Quantitative yeast 2-hybrid analysis. Id proteins expressed as gal4 DNA binding domain fusions were tested with class A and class B targets expressed as gal4 transactivation domain fusions. A, interaction of Id proteins with class A factors. B, interaction of Id proteins with MRFs. E12 and E47 (also expressed as binding domain fusions) are shown as strong positive controls. C, interaction of Id proteins with the hematopoietic factors. E2-2 (also expressed as a binding domain fusion) is shown as a positive control. The values shown represent the average of three independent determinations (with standard errors of <10% in each case). Expression of each protein was independently verified by Western blotting (Fig. 2).
[View Larger Version of this Image (29K GIF file)]


Fig. 2. Western blot analysis of yeast 2-hybrid fusion proteins. A, Id proteins expressed in pGBT9 were detected with an anti-gal4 DNA binding domain antibody. B-D, expression of the hematopoietic factors, E proteins, and MRFs, expressed in pGAD424, were detected with an anti-gal4 activation domain antibody. Untransformed Y153 lysates were used as controls. A size marker (in kilodaltons) is shown. In other experiments (not shown), we have determined that the levels of proteins shown here do not change when they are co-expressed with other bHLH member proteins.
[View Larger Version of this Image (35K GIF file)]

MRFs were also investigated for homodimerization ability. MyoD, myogenin, and Myf-5 displayed weak homodimerization (less than 50 pg of beta -galactosidase detected), whereas MRF4/Myf-6 homodimerization was not observed. Neither the Ids nor the hematopoietic factors displayed discernible homodimerization ability in this assay (data not shown).

Co-immunoprecipitation Analysis

Co-IP of selected full-length in vitro translated proteins was employed to confirm the differences in dimerization properties identified by yeast 2-hybrid analysis (Fig. 3). Increasing amounts of Id1, Id2, or Id3 proteins were incubated with E12, and resultant heterodimers were precipitated with an anti-E12 polyclonal antibody (Fig. 3A). Consistent with the yeast 2-hybrid data (Fig. 1), all three Ids interacted strongly with E12 with any differences being on the order of less than 2-fold. In contrast, interactions between Id proteins and MyoD were considerably weaker and showed more pronounced differences than those observed with Id-E protein interactions. For example, Id1 and Id2 showed comparable interactions with MyoD, whereas Id3-MyoD interactions were significantly weaker. These results were in good agreement with the results obtained by the 2-hybrid system. All Ids also bound very weakly to MRF4/Myf-6 (Fig. 3C) and not at all to Scl/Tal-1 (Fig. 3D). From these experiments, we conclude that the strengths of Id-E protein and Id-MRF interactions qualitatively and quantitatively reflected those observed in yeast. Furthermore, our results indicate that the dimerization properties of full-length proteins are not significantly different from those of the isolated HLH domains expressed in yeast.


Fig. 3. Co-immunoprecipitation of in vitro translated full-length proteins. E12 (A), MyoD (B), MRF4/Myf-6 (C), and Scl/Tal-1 (D) programmed reticulocyte lysates were incubated with Id1, Id2, and Id3 programmed lysates. Protein complexes were captured with anti-E12, MyoD, or Id polyclonal antibodies and reactions resolved by 12% SDS-PAGE. Quantitative determination of "captured" protein relative to Id was performed by PhosphorImage analysis, and values were normalized for methionine content. Determinations were performed at least twice, and representative graphs are shown.
[View Larger Version of this Image (26K GIF file)]

Mammalian 2-Hybrid Analysis

The observation that the Ids displayed the widest range of interactions with MyoD and Myf-5 led us to investigate whether such differences were maintained in mammalian cells (Fig. 4). Id1, Id2, and Id3 were expressed as gal4 DNA binding domain fusions, whereas MyoD and Myf-5 were expressed as VP16 transactivation domain fusions (56). Each was tested for its ability to activate a reporter vector in HeLa cells (Fig. 4A). E47, which displays strong interactions with each Id in yeast (Fig. 1A), was also expressed as a VP16 fusion as a positive control for Id dimerization activities. Appreciable CAT conversion was seen when either Id1 or Id2 was co-expressed with either MyoD or Myf-5 (Fig. 4B), whereas Id3 interaction with either of the myogenic factors was only marginally above background. These observations were generally consistent with both the yeast 2-hybrid data and with the co-IP experiments (Figs. 1 and 3). As the Ids differed in their ability to dimerize with the MRFs, we investigated their ability to bind E47 (Fig. 4B). Each was found to generate comparable high levels of CAT activity as might have been predicted from our yeast 2-hybrid results (Fig. 1A). Thus the reduced ability of Id3 to interact with MyoD or Myf-5 cannot simply be explained by its differential expression. Our results in both mammalian cells and in yeast appear to reflect the true dimerization preferences of the Id proteins under study.


Fig. 4. Mammalian 2-hybrid analysis. A, an interaction between an MRF (expressed in pNLVP16) and an Id protein (expressed in pSG424) will result in the activation of a CAT reported gene bearing tandemly repeated gal4 binding sites in its promoter. B, HLH domains of Id1, Id2, and Id3, expressed as gal4 DNA binding domain (BD) fusions, were tested for their ability to interact with MyoD, Myf-5, or E47 expressed as VP16 transactivation domain (TAD) fusions. CAT conversion over background was determined by PhosphorImage analysis. Values shown represent the average of three independent experiments with standard errors of less than 10%.
[View Larger Version of this Image (29K GIF file)]

Id Repression of E Protein-MyoD Heterodimer Activity

By having established that the Ids interacted similarly with each E protein (Fig. 1A), we sought to determine the influence of each Id on the transcriptional activity of full-length E2A·MyoD heterodimers (Fig. 5). We had previously established that this combination of factors gave the highest levels of transactivation from the MCK-CAT reporter.2 The relative consistency of Id-E2A interactions in yeast suggested that each Id should disrupt E2A·MyoD complexes with comparable ability. Low levels of transactivation were observed when either 5 µg of MyoD or 1 µg of E47 or E12 was transfected alone. Co-transfection of these factors, however, generated significant CAT conversion, indicating that transactivation was mediated by an E2A·MyoD heterodimer and not by endogenous factors. The enhanced ability of MyoD to form heterodimers with E47 compared with E12 in yeast (Fig. 1B) was reflected in an increased ability of MyoD·E47 heterodimers to activate the MCK-CAT reporter. The introduction of increasing amounts of each Id led to the suppression of CAT activity in a dose-dependent fashion, with a maximal 2-3-fold reduction in transactivation observed at the highest input Id concentration. In metabolic labeling experiments, the expression of each Id was determined to be comparable (data not shown).


Fig. 5. Disruption of E2A·MyoD complexes by Ids. Ids were tested in their ability to disrupt E47·MyoD complexes (dark shading) or E12·MyoD complexes (light shading). Values are normalized relative to MyoD·E47 conversion. The average of at least three experiments is shown.
[View Larger Version of this Image (33K GIF file)]

Id Protein Helix Swaps and Site-directed Mutagenesis

To map the amino acid residues responsible for the differential binding capabilities of Id proteins with respect to the MRFs, helix swaps were generated, and site-directed mutagenesis was performed (Fig. 6). All mutants were tested in yeast for their ability to bind E12, and all were found to bind with similar avidity, varying over an approximate 2-fold range (Fig. 6, last column). These results were anticipated based on our observations that wild-type Id1 and Id3 interacted to a comparable extent with E12 (Fig. 1A). Initially, chimeras containing the first helix of Id1 and the loop-helix 2 region of Id3 or the first helix of Id3 and the loop-helix 2 region of Id1 were constructed and tested for interaction with all four MRFs (Fig. 6, lines 3 and 4). These experiments clearly demonstrated that the region determining the specificity of interactions resided in the first helix and/or in the amino-terminal region immediately adjacent to this. Based on this observation, the three amino acid residues that distinguish the first helices of Id1 and Id3 were altered sequentially to convert Id1 to Id3 and vice versa. Altering individual tyrosine, glycine, and lysine residues of Id1 to the corresponding aspartic acid, histidine, and arginine residues of Id3, respectively, reduced binding in each case (Fig. 6, lines 5, 7, and 9). However, the relative importance of each residue for dimerization was dependent upon the MRF under study. For example Id1/3 (G92H) showed a 3-fold reduction in the ability to bind MyoD but a 14-fold reduction in the ability to bind Myf-5 (compare Fig. 6, lines 3 and 7). In contrast Id1/3 (K98R) showed a 12-fold reduction in MyoD binding but only a 4-fold reduction in myogenin binding (compare Fig. 6, lines 3 and 9). Similarly, no single Id3 to Id1 mutation restored maximal binding (Fig. 6, lines 6, 8, and 10). This demonstrates that each residue, even the conserved lysine of Id1 and arginine of Id3, contributes to binding specificity although the relative importance of each residue is dependent upon the MRF target. To investigate possible additive effects, two further sets of Id3 mutations were investigated for their ability to restore Id1-like binding. A double mutant (Fig. 6, line 11), created by altering the aspartic acid and histidine residues of Id3/1 to the complementary tyrosine and glycine residues of Id1, resulted in almost full binding to MyoD, increased binding to Myf-5, and weak binding to MRF4/Myf-6. This double mutant did not, however, restore myogenin binding. Even when all three residues were altered to those of Id1 (Fig. 6, line 12), no increase was seen in Myf-5 binding when compared with the double mutant. Some binding was seen to myogenin, whereas MRF4/Myf-6 binding was undetectable. These data suggested that helix 1 residues are sufficient for MyoD recognition but that additional residues upstream of helix 1 appear to be required for full dimerization with the other three myogenic factors. To investigate the upstream requirement further, a series of deletions were made in the Id1/3 swap background. The initial deletion of six amino acids at the extreme NH2 terminus of the Id1/3 sequence (Fig. 6, line 13) had a minimal effect on binding (<2-fold) with the exception of Myf-5 whose binding was reduced approximately 3-fold (Fig. 6, lines 3 and 13). The deletion of a further six residues (Fig. 6, line 14) resulted in the abrogation of myogenin and MRF4/Myf-6 binding although little additional effect was seen with respect to Myf-5 and MyoD. Finally, an internal deletion of the six residues immediately adjacent to the amino terminus of the first helix (Fig. 6, line 15) severely inhibited dimerization with all MRFs, although this was least obvious with MyoD. Interestingly, all of the individual deletion mutants (Fig. 6, lines 13-15) bound E12 as well as either of the wild-type Ids (with <2-fold differences). From these studies, it appears that complete MyoD and Myf-5 interactions with Id1 require similar amino acid residues. The residues facilitating MyoD and Myf-5 binding are not sufficient for myogenin and MRF4/Myf-6 binding, and these latter factors require additional, upstream amino acids. Binding by E12 would appear not to require any of these upstream residues.


Fig. 6. Id protein helix swaps and site-directed mutagenesis. A series of Id hybrid molecules were tested in their ability to bind all four MRFs and E12 using a quantitative yeast 2-hybrid assay, performed in triplicate. The amount of beta -galactosidase enzyme generated per 107 cells (ng) for each set of interactions is shown in the right hand columns. Standard errors were less than 5% in each case.
[View Larger Version of this Image (35K GIF file)]

A select number of the Id "helix swap" proteins depicted in Fig. 4 were examined using the mammalian two-hybrid system. In these experiments, the HLH domains of Id1/3, Id3/1, and Id1/3 D80-85 were cloned into the pSG424 vector and transfected into HeLa cells together with either pNLVPMyoD or pNLVPMyf5. As shown in Fig. 7, these results recapitulated those observed in yeast. Neither Id3, Id3/1, nor Id1/3 D80-85 gave a detectable interaction with either MyoD or Myf5. In contrast, Id1 interacted strongly. That each of the Id proteins was expressed was confirmed in control experiments showing that all five Id fusion proteins depicted in Fig. 7 interacted strongly with a pNLVP16 fusion of the E12 bHLH domain (not shown).


Fig. 7. Mammalian 2-hybrid interactions of MyoD and Myf5 with select Id1 and Id3 mutants. The pNLVP vectors used were the same as those described in Fig. 6. The Id1/3, Id3/1, and Id1D80-85 mutant HLH domains shown in Fig. 6 were amplified by PCR and cloned into the pSG424 vector. The indicated amounts of each plasmid along with pGal5E472CAT (5 µg/plate) and a CMVbeta -gal (2 µg/plate) were transfected into HeLa cells using a calcium phosphate precipitation procedure and assayed for beta -galactosidase and CAT 2 days later.
[View Larger Version of this Image (16K GIF file)]


DISCUSSION

bHLH proteins are involved in diverse aspects of cellular physiology, from establishing the topography of the early embryo (e.g. Twist) to promoting cellular transformation, proliferation, and apoptosis (e.g. c-Myc) and ultimately to the regulation of terminal differentiation programs such as myogenesis (the MRFs) (25, 57, 58). As an increasing number of such proteins are characterized, it is apparent that spatial and temporal expression patterns combine with a hierarchical network of specific protein-protein interactions to provide precise control of many cellular processes.

A variety of biochemical, genetic, and in vivo approaches have been taken in the investigation of dimerization potential, sequence-specific DNA binding, and transcriptional activity of bHLH factors (35, 41, 43, 56, 59-62). Although our investigation generally considers only one aspect of these activities, dimerization, we feel that a comprehensive understanding of the relative affinities displayed by a group of key factors may provide insight into mechanisms of transcriptional activation. As the function of the myogenic factors both in establishing the myoblast lineage and initiating terminal differentiation is reasonably well described, myogenesis may provide a useful model for other tissue-specific differentiation pathways (reviewed in Ref. 58).

Numerous groups have reported the ability of class A, class B, and Id proteins to homo- and heterodimerize. Sun and Baltimore (60) reported the dissociation constants (Kd) for MyoD homodimers, E47 homodimers, and E47·MyoD heterodimers to be 6.8 × 10-4, 1.5 × 10-5, and 1.9 × 10-6 M, respectively (60). These differences are remarkably consistent with the values of 0.05, 1.5, and 24 ng of beta -galactosidase obtained for these interactions in our study. Similarly, Estojak et al. (63) reported that high, intermediate, and low level interactions, determined in a semi-quantitative yeast 2-hybrid system, accurately reflected calculated Kd values (63). Other yeast 2-hybrid analyses have shown that Id1 and the class B factors MyoD and Scl/Tal-1 bind to the class A factors E2-2 and E12 (43, 44). Loveys et al. (35) demonstrated the ability of Id3 to interact with E12, E47, HEB, and MyoD both in yeast and in vitro, observing that Id3 interacted strongly with each E protein but with reduced ability to MyoD (35). They were also able to show that Id3 could repress E protein-mediated transcription from a multimerized immunoglobulin E box reporter. Id1 and Id2 bind at low levels to MyoD and very weakly, if at all, to Scl/Tal-1 as demonstrated by co-IP and glutathione S-transferase-pull down analysis (28, 34, 41). Mammalian 2-hybrid approaches have also demonstrated the ability of Id1 to interact with both MyoD and E12 and of Scl/Tal-1 to interact with E47 (56, 64). These reports concur with the general observation that class A-class B and Id-class A complexes are more stable than Id-class B complexes. Our study not only confirms and extends previous reports of HLH protein dimerization potentials but attempts to provide a consistent comparison of a broad range of interactions.

All three Id proteins tested here interacted strongly with all class A factors, consistent with their role in the sequestration of these ubiquitous proteins. Although Id-class A interactions displayed the strongest and most consistent interactions among the series of factors tested, each Id nevertheless displayed a discrete "fingerprint" of preferred class A partner. Specific patterns of Id-MRF interactions were also observed, although these interactions were considerably weaker and showed greater variability than those of Id-class A interactions. The finding that Id-MRF interactions were conserved, in contrast to Id-hematopoietic factor interactions, suggests that the Ids may have a role in myogenesis that is distinct from that in hematopoiesis. Finally, the overlap in Id-class B and Id-class A interaction strengths provides additional reason to believe that the former may be physiologically relevant. When the Ids were expressed as full-length proteins in vitro, or as HLH domains in human cells, the differences in relative affinities observed in yeast persisted (Figs. 3 and 4), indicating that the discrete range of interactions accurately reflects the in vivo situation and was not merely a consequence of the expression of mammalian genes in yeast.

Homodimerization of bHLH proteins seems to be important in certain contexts. For example, E47 homodimers are sufficient to activate immunoglobulin gene expression (65). MyoD is also capable of binding DNA as a homodimer, although it has not been established if this is biologically significant as the concentrations required for homodimerization in vitro may not be achievable in vivo (8). On the other hand, it is conceivable that apparently weak interactions are stabilized by accessory factors or that low concentrations of MyoD homodimers are sufficient to initiate the myogenic cascade, and this may be sensitive to direct Id-mediated suppression. Therefore, cell fate determination may in part depend on the relative level of distinct Id proteins to create a permissive environment. Interestingly, our observations indicate that the Ids bind with the highest affinity those myogenic factors involved in myoblast lineage determination (MyoD and Myf-5), whereas those MRFs active post-mitotically (myogenin and MRF4/Myf-6), a time when Id levels are generally low or undetectable, bind Ids considerably less well.

The differential affinities of the Id proteins for both the class A and class B MRFs could be explained if these latter proteins homodimerized. Under such conditions, there might exist a differential availability of E proteins or MRFs for Ids due to their sequestration in homodimeric form. In other experiments, we have examined the ability of the Ids, the E proteins, and the class B MRFs and hematopoietic factors to homodimerize using the same two-hybrid system shown in Fig. 1.3 We detected homodimerization only with E47, although at levels that were 10-30-fold lower than its interaction with any of the three Ids. Thus, limitation of E protein accessibility to the Ids due to homodimeric sequestration appears unable to explain our results.

Having demonstrated that Id proteins bind each class A molecule and a subset of class B molecules, we tested the ability of each Id to suppress transactivation from a muscle-specific E box by an E2A·MyoD complex in vivo (Fig. 5). Id1, Id2, and Id3 were found to disrupt E2A·MyoD complexes with comparable ability, consistent with the yeast data. Interestingly, an apparent excess of Id was unable to completely abrogate binding. Other studies on the effect of Id1 or Id3 on the transactivation potential of MyoD or E proteins have also reported a less than complete suppression of activity, with even greater excesses of Id than we have utilized (28, 35). Investigation of the activity of any transcription factor in isolation is complicated by the influence of endogenous factors. Having established conditions in which each factor alone results in minimal transactivation, we can be certain that the repressive effect of the Ids is exerted only on the factors under study.

The observation that the Ids differed in their ability to recognize myogenic partners led us to investigate the precise residues responsible for this specificity (Fig. 6). Dimeric bHLH complexes bound to DNA are predicted to form a parallel 4-helix bundle stabilized by a hydrophobic core as well as by electrostatic interactions (2, 8, 62). Shirakata et al. (62) reported that the alteration of five non-hydrophobic residues distinguishing chicken MyoD from the Drosophila MyoD homologue nautilus (which does not bind E12) led to a progressive reduction in MyoD·E12 dimer formation, suggesting that these residues confer an additive effect on binding (62). Likewise, in our study, no single residue was able to confer Id1-like characteristics. Rather a combination of non-conserved residues was involved in MRF binding. However, these residues did not appear to be important for Id-class A interaction (Fig. 6). Two non-conserved residues in the first helix were sufficient for almost complete MyoD binding. These residues, Tyr-88 and Gly-92 of Id1, are uncharged, whereas the corresponding residues of Id3 (Asp-42 and His-46) confer a negative and positive charge, respectively. Thus, the differences in Id binding (with respect to MyoD) may be consistent with the "charged pair" model which suggests that attractive or repulsive forces between contacting residues in the helices of aligned molecules act to stabilize or destabilize dimer formation (62). The residue at the third position also influences heterodimerization even though this represents a conservative change (Lys-98 in Id1 to Arg-52 in Id3). In this case, the larger arginine side chain may act to destabilize Id3·MRF complexes. Despite the obvious importance of these residues, the complete conversion of Id3 helix 1 to that of Id1 helix 1 restored only 50% Myf-5 binding and only minimal interaction with myogenin and MRF4/Myf-6, suggesting that additional residues exert an effect. Indeed, a series of amino-terminal deletions (Fig. 6, lines 13 and 14) demonstrated that a region outside the HLH domain was important for Id1-MRF interactions, particularly with respect to myogenin and MRF4/Myf-6. Interestingly, these deletions did not appear to influence E12 binding. Upstream sequences may not be involved in establishing dimeric complexes as such, but rather in stabilizing pre-formed interactions determined by residues in the HLH region. Such subtle cooperative effects might be expected to contribute more to weak Id-myogenin or Id-MRF4/Myf-6 interactions than to stronger associations. Goldfarb et al. (43) used random mutagenesis in conjunction with a yeast 2-hybrid system to generate both hydrophobic and hydrophilic substitutions which enhanced the ability of Scl/Tal-1 to recognize E2-2 (43). Such alterations were again found to have a synergistic effect on dimer stability. More extensive mutagenesis is required to fully understand the diversity of dimer preferences displayed by HLH factors. The quantitative yeast 2-hybrid system described in this report provides a useful tool for this purpose.

Regions other than the HLH domain, such as the putative leucine zipper present in the class A proteins, have the potential to modulate interactions (1, 11, 12). Because our co-IP findings with full-length proteins are consistent with both our yeast and mammalian 2-hybrid results, we infer that other potential dimerization domains do not contribute significantly to the interactions observed here. However, we have not evaluated the possible influence of post-translational modifications on dimerization (47, 59, 66, 67).

Although HLH activity may be modulated in vivo, the key differences in binding characteristics presented in this study may play a fundamental role in the establishment of differentiation programs. There still exists, however, a great deal of redundancy. One apparent paradox is that there is little evidence, as yet, for the combinatorial variation in E box binding allowed by heterodimerization between different class B groups and any class A factor. For example, all class A·MRF dimers so far studied efficiently bind an element in the muscle creatine kinase enhancer, and binding site selection indicates that Scl/Tal-1, Tal-2 and Lyl-1 heterodimers with E2-2 all recognize the same putative hematopoietic-specific element (68, 69). Spatial and temporal differences in the expression of factors with apparently conserved function may also explain some of the apparent overlap. Alternatively, redundancy may reflect the need for cooperative occupancy of proximal promoter elements by accessory factors. A distinct group of tissue-restricted non-bHLH transcription factors have been identified, such as the myocyte enhancer family (MEF-2) in muscle and the zinc finger GATA factors in erythropoiesis (70, 71). These may act to enhance the transcriptional activity of bHLH dimers, thereby modulating lineage-specific gene expression. Indeed, the apparent redundancy in function may mask the requirement for a subtle gradient of both ubiquitous and tissue-specific factors to facilitate the controlled establishment of the differentiated phenotype.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant HL33741 (to E. V. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
par    To whom correspondence should be addressed: Section of Hematology/Oncology, Children's Hospital Medical Center, 3705 Fifth Ave., Pittsburgh, PA 15213. Tel.: 412-692-6796; Fax: 412-692-5723.
1   The abbreviations used are: bHLH, basic-helix-loop-helix; CAT, chloramphenicol acetyltransferase; MCK, muscle creatinine kinase; MRF, myogenic regulatory factor; IP, immunoprecipitation; DMEM, Dulbecco's modified Eagle's medium; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; CMV, cytomegalovirus.
2   K. Langlands, X. Yin, G. Anand, and E. V. Prochownik, unpublished data.
3   K. Langlands and E. V. Prochownik, unpublished data.

ACKNOWLEDGEMENTS

We thank members of our laboratory for helpful discussions and advice and Geneva Jordan for skilled secretarial assistance.


REFERENCES

  1. Murre, C., McCaw, P. S., and Baltimore, D. (1989) Cell 56, 777-783 [Medline] [Order article via Infotrieve]
  2. Ellenberger, T., Fass, D., Arnaud, M., and Harrison, S. C. (1994) Genes Dev. 8, 970-980 [Abstract]
  3. Ferré-D'Amaré, A. R., Prendergast, G. C., Ziff, E. B., and Burley, S. K. (1993) Nature 363, 38-45 [CrossRef][Medline] [Order article via Infotrieve]
  4. Ma, P. C. M., Rould, M. A., Weintraub, H., and Pabo, C. O. (1994) Cell 77, 451-459 [Medline] [Order article via Infotrieve]
  5. Voronova, A., and Baltimore, D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4722-4726 [Abstract]
  6. Murre, C., McCaw, P. S., Vaessin, H., Caudy, M., Jan, L. Y., Jan, Y. N., Cabrera, C. V., Buskin, J. N., Hauschka, S. D., Lassar, A. B., Weintraub, H., and Baltimore, D. (1989) Cell 58, 537-544 [Medline] [Order article via Infotrieve]
  7. Blackwell, T. K., and Weintraub, H. (1990) Science 250, 1104-1110 [Medline] [Order article via Infotrieve]
  8. Davis, R. L., Cheng, P.-F., Lassar, A. B., and Weintraub, H. (1990) Cell 60, 733-746 [Medline] [Order article via Infotrieve]
  9. Ephrussi, A., Church, G. H., Tonegawa, S., and Gilbert, W. (1985) Science 227, 134-140 [Medline] [Order article via Infotrieve]
  10. Murre, C., and Baltimore, D. (1992) in Transcriptional Regulation (Mcknight, S. L., and Yamamoto, K. R., eds), pp. 861-879, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  11. Henthorn, P., Kiledjian, M., and Kadesch, T. (1990) Science 247, 467-470 [Medline] [Order article via Infotrieve]
  12. Hu, J.-S, Olson, E. N., and Kingston, R. E. (1992) Mol. Cell. Biol. 12, 1031-1042 [Abstract]
  13. Lassar, A. B., Davis, R. L., Wright, W. E., Kadesch, T., Murre, C., Voronova, A., Baltimore, D., and Weintraub, H. (1991) Cell 66, 305-315 [Medline] [Order article via Infotrieve]
  14. Begley, C. G., Aplan, P. D., Denning, S. M., Haynes, B. F., Waldmann, T. A., and Kirsch, I. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 10128-10132 [Abstract]
  15. Braun, T., Buschhausen-Denker, G., Bober, E., Tannich, E., and Arnold, H. H. (1989) EMBO J. 8, 701-709 [Abstract]
  16. Braun, T., Bober, E., Winter, N., Rosenthal, N., and Arnold, H. H. (1990) EMBO J. 9, 821-831 [Abstract]
  17. Davis, R. L., Weintraub, H., and Lassar, A. B. (1987) Cell 51, 987-1000 [Medline] [Order article via Infotrieve]
  18. Edmonson, D. G., and Olson, E. N. (1989) Genes Dev. 3, 628-640 [Abstract]
  19. Mellentin, J. D., Smith, S. D., and Cleary, M. L. (1989) Cell 58, 77-83 [Medline] [Order article via Infotrieve]
  20. Rhodes, S. J., and Konieczny, S. F. (1989) Genes Dev. 3, 2050-2061 [Abstract]
  21. Xia, Y., Brown, L., Yang, C. Y.-C., Tsan, J. T., Siciliano, M., Espinosa, R., LeBeau, M., and Baer, R. E. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11416-11420 [Abstract]
  22. Johnson, J. E., Birren, S. J., and Anderson, D. J. (1990) Nature 346, 858-861 [CrossRef][Medline] [Order article via Infotrieve]
  23. Lee, J. E., Hollenberger, S. M., Snider, L., Turner, D. L., Lipnick, N., and Weintraub, H. (1995) Science 268, 836-844 [Medline] [Order article via Infotrieve]
  24. Naya, F. J., Stellrecht, C. M., and Tsai, M.-J. (1995) Genes Dev. 9, 1009-1019 [Abstract]
  25. Spicer, D. B., Rhee, J., Cheung, W. L., and Lassar, A. B. (1996) Science 272, 1476-1480 [Abstract]
  26. Cserjesi, P., Brown, D., Ligon, K. L., Lyons, G. E., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Olson, E. N. (1995) Development 121, 1099-1110 [Abstract/Free Full Text]
  27. Tontonoz, P., Kim, J. B., Graves, R. A., and Spiegelman, B. (1993) Mol. Cell. Biol. 13, 4753-4759 [Abstract]
  28. Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L., and Weintraub, H. (1990) Cell 61, 49-59 [Medline] [Order article via Infotrieve]
  29. Biggs, J., Murphy, E. V., and Israel, M. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1512-1516 [Abstract]
  30. Christy, B. A., Sanders, L. K., Lau, L. F., Copeland, N. G., Jenkins, N. A., and Nathans, D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1815-1819 [Abstract]
  31. Deed, R. W., Bianchi, S. M., Atherton, G. T., Johnston, D., Santibanez-Koref, M., Murphy, J. J., and Norton, J. D. (1993) Oncogene 8, 599-607 [Medline] [Order article via Infotrieve]
  32. Ellmeier, W., Aguzzi, A., Kleiner, E., Kurzbauer, R., and Weith, A. (1992) EMBO J. 11, 2563-2571 [Abstract]
  33. Reichman, V., van Crüchten, I., and Sablitzky, F. (1994) Nucleic Acids Res. 22, 749-755 [Abstract]
  34. Sun, X.-H., Copeland, N. G., Jenkins, N. A., and Baltimore, D. (1991) Mol. Cell. Biol. 11, 5603-5611 [Medline] [Order article via Infotrieve]
  35. Loveys, D. A., Streiff, M. B., and Kato, G. J. (1996) Nucleic Acids Res. 24, 2813-2820 [Abstract/Free Full Text]
  36. Jen, Y., Weintraub, H., and Benezra, R. (1992) Genes Dev. 6, 1466-1479 [Abstract]
  37. Kreider, B. L., Benezra, R., Rovera, G., and Kadesch, T. (1992) Science 255, 1700-1702 [Medline] [Order article via Infotrieve]
  38. Shoji, W., Yamamoto, T., and Obinata, M. (1994) J. Biol. Chem. 269, 5078-5084 [Abstract/Free Full Text]
  39. Sun, X.-H. (1994) Cell 79, 893-900 [Medline] [Order article via Infotrieve]
  40. Wilson, R. B., Kiledjian, M., Shen, C.-P., Benezra, R., Zwollo, P., Dymecki, S., Desiderio, S. V., and Kadesch, T. (1991) Mol. Cell. Biol. 11, 6185-6191 [Medline] [Order article via Infotrieve]
  41. Hsu, H.-L., Wadman, I., and Baer, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3181-3185 [Abstract]
  42. Fields, S., and Song, O. (1989) Nature 340, 245-246 [CrossRef][Medline] [Order article via Infotrieve]
  43. Goldfarb, A. N., Lewandowska, K., and Shoham, M. (1996) J. Biol. Chem. 271, 2683-2688 [Abstract/Free Full Text]
  44. Staudinger, J., Perry, M., Elledge, S. J., and Olson, E. N. (1993) J. Biol. Chem. 268, 4608-4611 [Abstract/Free Full Text]
  45. Dang, C. V., Barrett, J., Villa-Garcia, M., Resar, L. M., Kato, G. J., and Fearon, E. R. (1991) Mol. Cell. Biol. 11, 954-962 [Medline] [Order article via Infotrieve]
  46. Sadowski, I., and Ptashne, M. (1989) Nucleic Acids Res. 17, 7539 [Medline] [Order article via Infotrieve]
  47. Neilsen, A. L., Pallisgaard, N., Pederson, F. S., and Jorgenson, P. (1992) Mol. Cell. Biol. 12, 3449-3459 [Abstract]
  48. Soosaar, A., Chiaramello, A., Zuber, M. X., and Neuman, T. (1994) Mol. Brain Res. 25, 176-180 [Medline] [Order article via Infotrieve]
  49. Walker, M. D., Park, C. W., Rosen, A., and Aronheim, A. (1990) Nucleic Acids Res. 18, 1159-1166 [Abstract]
  50. Aronheim, A., Shiran, R., Rosen, A., and Walker, M. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8063-8067 [Abstract/Free Full Text]
  51. Lillie, J. W., and Green, M. R. (1989) Nature 338, 39-44 [CrossRef][Medline] [Order article via Infotrieve]
  52. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1993) Current Protocols In Molecular Biology, 2nd Ed., John Wiley & Sons, Inc., New York
  53. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  54. Apel, I., Yu, C. L., Wang, T., Dobry, C., Van Antwerp, M. E., Jove, R., and Prochownik, E. V. (1992) Mol. Cell. Biol. 12, 3356-3364 [Abstract]
  55. Brennan, T. J., Edmonson, D. G., and Olson, E. N. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3822-3826 [Abstract]
  56. Finkel, T., Duc, J., Fearon, E. R., Dang, C. V., and Tomaselli, G. F. (1993) J. Biol. Chem. 268, 5-8 [Abstract/Free Full Text]
  57. DePinho, R. A., Schreiber-Agus, N., and Alt, F. W. (1991) Adv. Cancer Res. 57, 1-46 [Medline] [Order article via Infotrieve]
  58. Olson, E. N., and Klein, W. H. (1994) Genes Dev. 8, 1-8 [CrossRef][Medline] [Order article via Infotrieve]
  59. Klein, E. S., Simmons, D. M., Swanson, L. W., and Rosenfeld, M. G. (1993) Genes Dev. 7, 55-71 [Abstract]
  60. Sun, X.-H., and Baltimore, D. (1991) Cell 64, 459-470 [Medline] [Order article via Infotrieve]
  61. Zhuang, Y., Cheng, P., and Weintraub, H. (1996) Mol. Cell. Biol. 16, 2898-2905 [Abstract]
  62. Shirakata, M., Friedman, F. K., Wei, Q., and Paterson, B. M. (1993) Genes Dev. 7, 2456-2470 [Abstract]
  63. Estojak, J., Brent, R., and Golemis, E. A. (1995) Mol. Cell. Biol. 15, 5820-5829 [Abstract]
  64. Wadman, I., Li, J., Bash, R. O., Forster, A., Osada, H., Rabbitts, T. H., and Baer, R. (1994) EMBO J. 13, 4831-4839 [Abstract]
  65. Shen, C. P., and Kadesch, T. (1995) Mol. Cell. Biol. 15, 18-24
  66. Springhorn, J. P., Singh, K., Kelly, R. A., and Smith, T. W. (1994) J. Biol. Chem. 269, 5132-5136 [Abstract/Free Full Text]
  67. Skerjanc, I. S., Truong, J., Filion, P., and McBurney, M. W. (1996) J. Biol. Chem. 271, 3555-3561 [Abstract/Free Full Text]
  68. Hsu, H.-L., Huang, L., Tsan, J. T., Funk, W., Wright, W. E., Hu, J.-S., Kingston, R. E., and Baer, R. E. (1994) Mol. Cell. Biol. 14, 1256-1265 [Abstract]
  69. Lassar, A. B., and Weintraub, H. (1992) in Transcriptional Regulation (Mcknight, S. L., and Yamamoto, K. R., eds), pp. 1037-1061, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  70. Molkentin, J. D., and Olson, E. N. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9366-9373 [Abstract/Free Full Text]
  71. Osada, H., Grutz, G., Axelson, H., Forster, A., and Rabbitts, T. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9585-9589 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.